arsenic trioxide has been researched along with Bone Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 15 (83.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Boehme, KA; Handgretinger, R; Lenz, JE; Riester, R; Schleicher, SB; Traub, F | 1 |
| Arenkiel, BR; Bado, I; Du, S; Goldstein, A; Gugala, Z; Li, Z; Liu, J; Rowley, DR; Tian, L; Wang, H; Wong, STC; Yang, M; Zhang, W; Zhang, XH; Zhao, H | 1 |
| Bai, J; Gu, J; Li, R; Li, W; Li, X; Mu, Y; Wang, X; Wang, Y; Yue, Z; Zhang, H; Zhong, L | 1 |
| Abematsu, M; Fujimoto, Y; Ishidou, Y; Kitajima, S; Kitamoto, S; Komiya, S; Maeda, S; Nagano, S; Nagao-Kitamoto, H; Nagata, M; Nakamura, S; Setoguchi, T; Tsuru, A; Yamamoto, T; Yokouchi, M; Yonezawa, S; Yoshioka, T | 1 |
| Feng, L; Feng, T; Huang, Y; Qi, W; Qiao, G; Shen, Z; Yao, Y | 1 |
| Guo, L; Li, R; Li, W; Li, X; Mu, Y; Su, X; Wang, X; Wang, Z; Yue, Z; Zhang, H; Zhong, L | 1 |
| Chen, TY; Chen, ZG; Gao, X; Huang, CW; Huang, XC; Li, ZB; Maimaiti, XY; Zhang, L | 1 |
| Guo, W; Jiao, G; Ren, C; Ren, T; Yang, K | 1 |
| Bao, X; Guo, W; Huang, Y; Liu, K; Ren, T; Wang, S; Zhang, F; Zheng, B | 1 |
| Boehme, KA; Handgretinger, R; Kluba, T; Nitsch, J; Riester, R; Schleicher, SB; Traub, F | 1 |
| Changliang, P; Tingting, R; Wei, G; Xinchang, L; Yi, Y | 1 |
| Li, R; Li, Y; Shi, Y; Wang, Y; Wei, Y; Zhang, H | 1 |
| Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M | 1 |
| Guo, W; Lu, XC; Ren, TT; Tang, GQ; Zhang, S; Zhao, FL | 1 |
| Alexander, D; Billups, CA; Houghton, PJ; Kang, MH; Kurmasheva, RT; Reynolds, CP; Smith, MA; Toretsky, JA | 1 |
| Beauchamp, EM; Uren, A | 1 |
| Fang, JZ; Li, KH; Xiao, T | 1 |
| Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
1 review(s) available for arsenic trioxide and Bone Neoplasms
| Article | Year |
|---|---|
A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Leukemia, Promyelocytic, Acute; Medulloblastoma; Oncogene Proteins; Oxides; Sarcoma, Ewing | 2012 |
17 other study(ies) available for arsenic trioxide and Bone Neoplasms
| Article | Year |
|---|---|
Interaction of arsenic trioxide and etoposide in Ewing sarcoma cell lines.
Topics: Arsenic Trioxide; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Multidrug Resistance-Associated Proteins; Phosphorylation; Sarcoma, Ewing; Zinc Finger Protein GLI1 | 2020 |
The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Arsenic Trioxide; Benzamides; Bone Neoplasms; Breast Neoplasms; Calcium; Calcium Signaling; Cell Line, Tumor; Cell Proliferation; Connexin 43; Everolimus; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Osteogenesis; Protein Kinase Inhibitors; Pyrazoles; RAW 264.7 Cells; Tumor Microenvironment; U937 Cells | 2018 |
Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; DNA Primers; Gene Silencing; Heme Oxygenase-1; Humans; Osteosarcoma; Oxides; Polymerase Chain Reaction; Reactive Oxygen Species | 2014 |
GLI2 is a novel therapeutic target for metastasis of osteosarcoma.
Topics: Adolescent; Adult; Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Child; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Nuclear Proteins; Osteosarcoma; Oxides; Zinc Finger Protein Gli2 | 2015 |
Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Osteosarcoma; Oxides; RNA, Small Interfering; Stathmin | 2014 |
Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Matrix Attachment Region Binding Proteins; Neoplasm Invasiveness; Osteosarcoma; Oxides; Phenotype; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2014 |
Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Osteosarcoma; Oxides; Systems Biology | 2014 |
Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Bone Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; G2 Phase Cell Cycle Checkpoints; Humans; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chondrosarcoma; DNA Demethylation; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Oxides; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Drug Synergism; Etoposide; Flow Cytometry; Humans; Oxides; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Tumor Cells, Cultured | 2016 |
Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteosarcoma; Oxides; Phosphorylation | 2010 |
Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Catalase; Cell Line, Tumor; Flow Cytometry; Glutathione; Humans; Osteosarcoma; Oxides; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2012 |
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2011 |
Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Topics: Anisomycin; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cytoskeleton; Humans; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase Inhibitors; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Sarcoma, Ewing | 2012 |
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Female; Growth Inhibitors; Mice; Mice, SCID; Oxides; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2012 |
[Experimental study on the apoptotic effect of arsenic trioxide on human osteosarcoma MG-63 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Humans; Osteosarcoma; Oxides; Tumor Cells, Cultured | 2002 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |